Literature DB >> 21253616

[The role of nailfold videocapillaroscopy in Raynaud's phenomenon monitoring and early diagnosis of systemic sclerosis].

M Cutolo1, C Pizzorni, M Meroni, G Zampogna, C Ferrone, E Alessandri, A Sulli.   

Abstract

Several connective tissue diseases, in particular systemic sclerosis (SSc), have Raynaud's phenomenon (RP) as their first clinical manifestation. Primary RP represents a benign condition often observed in otherwise healthy subjects, especially women: it is due to an exaggerated response to the physiological cold-induced vasospasm, whereas the secondary form of RP is typically associated with connective tissue diseases, especially SSc. Nailfold videocapillaroscopy (NVC), particulary after the recent technological advances, is a safe and reliable method to observe the microvascular structure and its early changes, especially during the transition from primary to secondary RP. In case of SSc, by considering validated patterns and scoring systems, NVC is the main tool that rheumatologists can rely on, besides the presence of specific auto-antibodies, to perform a very early diagnosis of the disease. This implies the possibility of early treatment of SSc, with an eye of predicting and preventing its major clinical complications.

Entities:  

Mesh:

Year:  2010        PMID: 21253616     DOI: 10.4081/reumatismo.2010.237

Source DB:  PubMed          Journal:  Reumatismo        ISSN: 0048-7449


  2 in total

1.  Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis.

Authors:  S Bellando-Randone; G Lepri; C Bruni; J Blagojevic; A Radicati; L Cometi; A De Paulis; M Matucci-Cerinic; S Guiducci
Journal:  Clin Rheumatol       Date:  2015-12-03       Impact factor: 2.980

2.  Prevalence of retinal changes in patients with systemic sclerosis: the association between retinal vascular changes and nailfold capillaroscopic findings.

Authors:  Saeedeh Shenavandeh; Mehrdad Afarid; Tarlaan Hasanaghaei; Mohammad Ali Nazarinia
Journal:  Reumatologia       Date:  2021-02-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.